145 Aufrufe 145 0 Kommentare 0 Kommentare

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

    Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper’s comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Hims & Hers Health Registered (A)!
    Short
    37,95€
    Basispreis
    0,20
    Ask
    × 10,33
    Hebel
    Zum Produkt
    Blatt
    Long
    33,18€
    Basispreis
    0,38
    Ask
    × 8,67
    Hebel
    Zum Produkt
    Blatt
    Präsentiert von
    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.
    Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss

    Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss

    Since launching in Germany in March 2023, Juniper has grown into a trusted partner for customers seeking evidence-based weight management care in a market where nearly 1 in 5 adults lives with obesity. Juniper’s program, backed by clinical research, pairs personalised treatment with consistent, high-touch clinical support, with a particular focus on connecting women to the weight loss care they need. With the acquisition of Eucalyptus, Hims & Hers brings additional resources and operational expertise to the evidence-based, personalised weight management care Juniper has provided to customers in Germany for years.

    "Germany has taken meaningful steps to recognize obesity as a chronic disease, but access to effective, personalised care still lags far behind the need," said Andrew Dudum, co-founder and CEO of Hims & Hers. "With this acquisition we can help close that gap at scale, bringing world-class technology and clinical infrastructure to a team that has already earned the trust of people across Germany."

    To best serve its customers in Germany, Hims & Hers will continue to invest in a local clinical approach, and patients will continue to be connected with providers who are licensed in the local region, understand the healthcare landscape they're navigating, and bring the expertise and clinical rigour this kind of care demands. Hims & Hers also looks forward to potentially introducing new categories of care to the market in the future.

    As Hims & Hers grows in Germany, continuity of care is a top priority. For customers already receiving care through Juniper, their treatment continues uninterrupted. Joining Hims & Hers gives the team in Germany the backing to keep building on a model that patients have come to trust, with more resources and reach behind it.

    Seite 1 von 3 





    Business Wire (engl.)
    0 Follower
    Autor folgen

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper’s comprehensive, clinically …

    Im Durchschnitt erleiden 7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten. Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige Anlagestrategien geeignet.
    Profitieren Sie von unserem Alleinstellungsmerkmal als den zentralen verlagsunabhängigen Wissens-Hub für einen aktuellen und fundierten Zugang in die Börsen- und Wirtschaftswelt, um strategische Entscheidungen zu treffen.
    • ✅ Größte Finanz-Community Deutschlands
    • ✅ über 550.000 registrierte Nutzer
    • ✅ rund 2.000 Beiträge pro Tag
    • ✅ verlagsunabhängige Partner ARIVA, FinanzNachrichten und BörsenNews
    • ✅ Jederzeit einfach handeln beim SMARTBROKER+
    • ✅ mehr als 25 Jahre Marktpräsenz
    Aktien von A - Z: # A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    wallstreetONLINE bei X wallstreetONLINE bei Instagram wallstreetONLINE bei Facebook wallstreetONLINE bei Youtube wallstreetONLINE bei LinkedIn
    Unsere Apps: Apple App Store Icon Google Play Store Icon
    Wenn Sie Kursdaten, Widgets oder andere Finanzinformationen benötigen, hilft Ihnen ARIVA gerne. 

    Unsere User schätzen wallstreet-online.de: 4.8 von 5 Sternen ermittelt aus 285 Bewertungen bei www.kagels-trading.de
    Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr.
    Copyright © 1998-2026 Smartbroker Holding AG - Alle Rechte vorbehalten.
    Mit Unterstützung von: Ariva Smartbroker+
    Daten & Kurse von: TTMzero